Home

Arcus Biosciences, Inc. Common Stock (RCUS)

12.90
-0.48 (-3.59%)

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cancer treatment

The company specializes in creating a diverse portfolio of drug candidates that target various pathways involved in the immune response and tumor microenvironment, aiming to unlock the potential of the immune system in combating different types of cancers. Through its rigorous research and development efforts, Arcus strives to bring forth effective treatment options for patients and address significant unmet medical needs in oncology.

SummaryNewsPress ReleasesChartHistoricalFAQ
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 31, 2025
Ericsson Posts Weak Results, Joins East West Bancorp And Other Big Stocks Moving Lower In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 24, 2025
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · January 24, 2025
Expert Outlook: Arcus Biosciences Through The Eyes Of 8 Analystsbenzinga.com
Via Benzinga · November 6, 2024
Unveiling 5 Analyst Insights On Arcus Biosciencesbenzinga.com
Via Benzinga · October 21, 2024
Where Arcus Biosciences Stands With Analystsbenzinga.com
Via Benzinga · October 21, 2024
Demystifying Arcus Biosciences: Insights From 4 Analyst Reviewsbenzinga.com
Via Benzinga · October 3, 2024
Breaking Down Arcus Biosciences: 4 Analysts Share Their Viewsbenzinga.com
Via Benzinga · August 9, 2024
This Abbott Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesdaybenzinga.com
Via Benzinga · October 8, 2024
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q2 2024investorplace.com
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 8, 2024
Cracking The Code: Understanding Analyst Reviews For Arcus Biosciencesbenzinga.com
Via Benzinga · July 8, 2024
After Disappointing Bladder Cancer Data, Gilead Announces Encouraging Data From Gastric, Colorectal Cancer Studiesbenzinga.com
Gilead Sciences and Arcus Biosciences report sustained efficacy and safety in the Phase 2 EDGE-Gastric study for upper GI cancers, showing improved progression-free survival and objective response rates. New data from the ARC-9 study highlights significant survival benefits in metastatic colorectal cancer.
Via Benzinga · June 3, 2024
12 Health Care Stocks Moving In Friday's Pre-Market Sessionbenzinga.com
Via Benzinga · May 24, 2024
Navigating 5 Analyst Ratings For Arcus Biosciencesbenzinga.com
Via Benzinga · March 25, 2024
Critical Insights From Arcus Biosciences Analyst Ratings: What You Need To Knowbenzinga.com
Via Benzinga · February 22, 2024
Recap: Arcus Biosciences Q4 Earningsbenzinga.com
Via Benzinga · February 21, 2024
Earnings Scheduled For February 21, 2024benzinga.com
Companies Reporting Before The Bell • Gatos Silver (NYSEGATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via Benzinga · February 21, 2024
RCUS Stock Earnings: Arcus Biosciences Beats EPS, Beats Revenue for Q1 2024investorplace.com
RCUS stock results show that Arcus Biosciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 8, 2024
Preview: Arcus Biosciences's Earningsbenzinga.com
Via Benzinga · February 20, 2024
$320M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buyingbenzinga.com
Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.
Via Benzinga · February 1, 2024
Key Takeaways From Arcus Biosciences Analyst Ratingsbenzinga.com
Via Benzinga · January 30, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesdayinvestorplace.com
We're starting off trading on Tuesday with a look into the biggest pre-market stock movers traders need to keep an eye on today!
Via InvestorPlace · January 30, 2024
What 9 Analyst Ratings Have To Say About Arcus Biosciencesbenzinga.com
Via Benzinga · November 8, 2023
Arcus Biosciences: Q3 Earnings Insightsbenzinga.com
Via Benzinga · November 7, 2023
Pharma Giant Gilead Raises Stake In Cancer-Focused Arcus Biosciences, Stock Soarsbenzinga.com
Arcus Biosciences sees a 17.1% surge as Gilead Sciences amends collaboration, investing $320M at $21.00/share. Accelerate joint programs in cancer therapy.
Via Benzinga · January 30, 2024